Parameter Set Benzodiazepines 1 - LC-MS/MS

Order No.: 92917
Parameters:
1-OH-Midazolam, Chlordiazepoxide, Clobazam, Demoxepam, Diazepam, Medazepam, Midazolam, Norclobazam, Nordiazepam, Oxazepam, Prazepam, Temazepam, Tetrazepam

Encompasses 13 analytes
3PLUS1® Multilevel Calibrator Set available
Part of the MassTox® TDM Series A

CE-IVD validated product ready for IVDR within timeframes and transition periods specified by the IVDR 2017/746

Chlordiazepoxide

Clobazam

Norclobazam

Demoxepam

Diazepam

Nordiazepam

Medazepam

Midazolam

1-OH-Midazolam

Oxazepam

Prazepam

Temazepam

Tetrazepam

Clinical relevance

Benzodiazepines (BZD) are a group of psychoactive drugs with similar structures that are classified as sedatives. By virtue of their high lipophilicity they penetrate the blood-brain barrier easily and, after being resorbed, quickly reach the central nervous system, where they enhance the impact of the inhibiting neurotransmitter GABA. Besides anxiolytic and sedative effects, BZD also have anti-aggressive, hypnotic, muscle relaxant and anticonvulsive properties. The predominance of the individual effects varies with the special structures of the benzodiazepines and the administered dose. BZD in blood are present mostly bound nonspecifically to plasma proteins. They are metabolised mainly by the liver. The resulting metabolites are mostly pharmacologically active themselves, and in some cases they represent the actual active substance, e.g. nordiazem being metabolised from diazepam or clorazepate. The plasma elimination times are highly variable: from a few hours (midazolam) to several days (clobazam). The metabolites frequently have longer half-lives than the parent substance, so an enrichment of therapeutically effective substances in the blood can occur.

 

MassTox® TDM Series A

The MassTox® TDM Series A is a modular system that enables the determination of 200 analytes without changing column or mobile phases, thereby minimising the workload in the laboratory.
It consists of 3 parts:
• MassTox® TDM Basic Kit A
• Specific MassTox® TDM Parameter Set (13 different parameter sets available)
• Analytical column MassTox® TDM MasterColumn® A

More information about MassTox® TDM Series A

More Information
Method of Analysis LC-MS/MS
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Lower Limit of Quantitation 3 – 40 µg/l
Upper Limit of Quantification up to 1000–5050 μg/l
Intraassay CV = 2 – 5 %
Interassay CV = 2 – 7 %
Recovery 87 – 107 %
Specimen Serum/Plasma
Sample Preparation
  • Add 800 μl Internal Standard mix to 12 ml Precipitation Reagent to form mixture A
  • Pipette 50 μl sample/calibrator/MassCheck® control into a 1.5 ml reaction vial
  • Add 25 μl Extraction Buffer, mix briefly (vortex) and incubate 2 min.
  • Add 250 μl of mixture A and mix 30 s minimum (vortex) and centrifuge 5 min.
  • Dilute the supernatant with Dilution Buffer prior to injection depending on the instrument sensitivity
Run Time 3 min
Injection Volume 0.2 – 50 µl
Gradient

Isocratic (25 % Mobile Phase 1; 75 % Mobile Phase 2)

Ionisation ESI positive
MS/MS Mode MRM
Additional Info We recommend to set the scan time to a value that allows to achieve a minimum of 10 data points over the whole peak width.
Parameters 1-OH-Midazolam, Chlordiazepoxide, Clobazam, Demoxepam, Diazepam, Medazepam, Midazolam, Norclobazam, Nordiazepam, Oxazepam, Prazepam, Temazepam, Tetrazepam
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
As a customer please login or register to gain full access.

Chlordiazepoxide

Clobazam

Norclobazam

Demoxepam

Diazepam

Nordiazepam

Medazepam

Midazolam

1-OH-Midazolam

Oxazepam

Prazepam

Temazepam

Tetrazepam

Clinical relevance

Benzodiazepines (BZD) are a group of psychoactive drugs with similar structures that are classified as sedatives. By virtue of their high lipophilicity they penetrate the blood-brain barrier easily and, after being resorbed, quickly reach the central nervous system, where they enhance the impact of the inhibiting neurotransmitter GABA. Besides anxiolytic and sedative effects, BZD also have anti-aggressive, hypnotic, muscle relaxant and anticonvulsive properties. The predominance of the individual effects varies with the special structures of the benzodiazepines and the administered dose. BZD in blood are present mostly bound nonspecifically to plasma proteins. They are metabolised mainly by the liver. The resulting metabolites are mostly pharmacologically active themselves, and in some cases they represent the actual active substance, e.g. nordiazem being metabolised from diazepam or clorazepate. The plasma elimination times are highly variable: from a few hours (midazolam) to several days (clobazam). The metabolites frequently have longer half-lives than the parent substance, so an enrichment of therapeutically effective substances in the blood can occur.

 

MassTox® TDM Series A

The MassTox® TDM Series A is a modular system that enables the determination of 200 analytes without changing column or mobile phases, thereby minimising the workload in the laboratory.
It consists of 3 parts:
• MassTox® TDM Basic Kit A
• Specific MassTox® TDM Parameter Set (13 different parameter sets available)
• Analytical column MassTox® TDM MasterColumn® A

More information about MassTox® TDM Series A

More Information
Method of Analysis LC-MS/MS
Please note The freely available information on this website, in particular on the sample preparation, are not sufficient to work with our products. Please read instructions and warning notices on products and/or instruction manuals.
Lower Limit of Quantitation 3 – 40 µg/l
Upper Limit of Quantification up to 1000–5050 μg/l
Intraassay CV = 2 – 5 %
Interassay CV = 2 – 7 %
Recovery 87 – 107 %
Specimen Serum/Plasma
Sample Preparation
  • Add 800 μl Internal Standard mix to 12 ml Precipitation Reagent to form mixture A
  • Pipette 50 μl sample/calibrator/MassCheck® control into a 1.5 ml reaction vial
  • Add 25 μl Extraction Buffer, mix briefly (vortex) and incubate 2 min.
  • Add 250 μl of mixture A and mix 30 s minimum (vortex) and centrifuge 5 min.
  • Dilute the supernatant with Dilution Buffer prior to injection depending on the instrument sensitivity
Run Time 3 min
Injection Volume 0.2 – 50 µl
Gradient

Isocratic (25 % Mobile Phase 1; 75 % Mobile Phase 2)

Ionisation ESI positive
MS/MS Mode MRM
Additional Info We recommend to set the scan time to a value that allows to achieve a minimum of 10 data points over the whole peak width.
Parameters 1-OH-Midazolam, Chlordiazepoxide, Clobazam, Demoxepam, Diazepam, Medazepam, Midazolam, Norclobazam, Nordiazepam, Oxazepam, Prazepam, Temazepam, Tetrazepam
The following components are included in the kit:
The following products are not included in the kit but are required for the application of the method:
As a customer please login or register to gain full access.